Nature Communications (Nov 2021)
Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia
- Nadia El Khawanky,
- Amy Hughes,
- Wenbo Yu,
- Renier Myburgh,
- Tony Matschulla,
- Sanaz Taromi,
- Konrad Aumann,
- Jade Clarson,
- Janaki Manoja Vinnakota,
- Khalid Shoumariyeh,
- Cornelius Miething,
- Angel F. Lopez,
- Michael P. Brown,
- Justus Duyster,
- Lutz Hein,
- Markus G. Manz,
- Timothy P. Hughes,
- Deborah L. White,
- Agnes S. M. Yong,
- Robert Zeiser
Affiliations
- Nadia El Khawanky
- Precision Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI)
- Amy Hughes
- School of Medicine, Faculty of Health and Medical Sciences, University of Adelaide
- Wenbo Yu
- Centre for Cancer Biology, SA Pathology and University of South Australia
- Renier Myburgh
- Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Comprehensive Cancer Center Zurich (CCCZ)
- Tony Matschulla
- Institute of Experimental and Clinical Pharmacology and Toxicology, Division II, Faculty of Medicine, University of Freiburg
- Sanaz Taromi
- Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg
- Konrad Aumann
- Department of Pathology, Institute for Clinical Pathology, University Medical Center Freiburg
- Jade Clarson
- Precision Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI)
- Janaki Manoja Vinnakota
- Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg
- Khalid Shoumariyeh
- Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg
- Cornelius Miething
- Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg
- Angel F. Lopez
- School of Medicine, Faculty of Health and Medical Sciences, University of Adelaide
- Michael P. Brown
- School of Medicine, Faculty of Health and Medical Sciences, University of Adelaide
- Justus Duyster
- Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg
- Lutz Hein
- Institute of Experimental and Clinical Pharmacology and Toxicology, Division II, Faculty of Medicine, University of Freiburg
- Markus G. Manz
- Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Comprehensive Cancer Center Zurich (CCCZ)
- Timothy P. Hughes
- Precision Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI)
- Deborah L. White
- Precision Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI)
- Agnes S. M. Yong
- Precision Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI)
- Robert Zeiser
- Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg
- DOI
- https://doi.org/10.1038/s41467-021-26683-0
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 20
Abstract
The success of CAR-T cells for treating acute myeloid leukaemia (AML) is hampered by toxicity to normal cells and low CAR-T cell persistence. Here, the authors show that the demethylating compound 5′-Azacitdine increases anti-CD123 CAR-T cell cytotoxicity against AML.
